Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies GYNECOLOGIC ONCOLOGY Markman, M., Homesley, H., Norberts, D. A., Schink, J., Abbas, F., Miller, A., Soper, J., Teng, N., Hammond, N., Muggia, F., Israel, M., Sweatman, T. 1996; 61 (1): 90-93


AD-32 (N-trifluoroacetyladriamycin-14-valerate), an analogue of doxorubicin, was examined for intraperitoneal (ip) administration in a phase 2 trial involving 25 patients with advanced gynecologic malignancies. At an AD-32 dose of 600 mg/m2, the limiting toxicity was grade 4 neutropenia (64% of patients), while severe abdominal pain was relatively uncommon (12%). Intraperitoneal AD-32 administration was associated with a 200-fold pharmacokinetic advantage for cavity exposure, compared to the systemic compartment. At the 600 mg/m2 dose level, 4 of 9 patients (44%) with ascites experienced control of malignant fluid reaccumulation. Based on the results of this phase 1 trial, further exploration of a possible role for the ip administration of AD-32 in individuals with gynecological malignancies appears indicated, particularly in patients with either small volume residual disease after initial systemic chemotherapy or in those with intractable ascites.

View details for Web of Science ID A1996UC96100017

View details for PubMedID 8626124